417 related articles for article (PubMed ID: 29175542)
1. Defining a Cohort that May Not Require Repeat Prostate Biopsy Based on PCA3 Score and Magnetic Resonance Imaging: The Dual Negative Effect.
Perlis N; Al-Kasab T; Ahmad A; Goldberg E; Fadak K; Sayyid R; Finelli A; Kulkarni G; Hamilton R; Zlotta A; Ghai S; Fleshner N
J Urol; 2018 May; 199(5):1182-1187. PubMed ID: 29175542
[TBL] [Abstract][Full Text] [Related]
2. Multiparametric magnetic resonance imaging of the prostate can improve the predictive value of the urinary prostate cancer antigen 3 test in patients with elevated prostate-specific antigen levels and a previous negative biopsy.
Sciarra A; Panebianco V; Cattarino S; Busetto GM; De Berardinis E; Ciccariello M; Gentile V; Salciccia S
BJU Int; 2012 Dec; 110(11):1661-5. PubMed ID: 22564540
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of PCA3 and multiparametric MRI's: collective benefits before deciding initial prostate biopsy for patients with PSA level between 3-10ng/mL.
Okcelik S; Soydan H; Ates F; Berber U; Saygin H; Sonmez G; Karademir K
Int Braz J Urol; 2016; 42(3):449-55. PubMed ID: 27286106
[TBL] [Abstract][Full Text] [Related]
4. The roles of multiparametric magnetic resonance imaging, PCA3 and prostate health index-which is the best predictor of prostate cancer after a negative biopsy?
Porpiglia F; Russo F; Manfredi M; Mele F; Fiori C; Bollito E; Papotti M; Molineris I; Passera R; Regge D
J Urol; 2014 Jul; 192(1):60-6. PubMed ID: 24518780
[TBL] [Abstract][Full Text] [Related]
5. The Value of PSA Density in Combination with PI-RADS™ for the Accuracy of Prostate Cancer Prediction.
Distler FA; Radtke JP; Bonekamp D; Kesch C; Schlemmer HP; Wieczorek K; Kirchner M; Pahernik S; Hohenfellner M; Hadaschik BA
J Urol; 2017 Sep; 198(3):575-582. PubMed ID: 28373135
[TBL] [Abstract][Full Text] [Related]
6. Combined Clinical Parameters and Multiparametric Magnetic Resonance Imaging for Advanced Risk Modeling of Prostate Cancer-Patient-tailored Risk Stratification Can Reduce Unnecessary Biopsies.
Radtke JP; Wiesenfarth M; Kesch C; Freitag MT; Alt CD; Celik K; Distler F; Roth W; Wieczorek K; Stock C; Duensing S; Roethke MC; Teber D; Schlemmer HP; Hohenfellner M; Bonekamp D; Hadaschik BA
Eur Urol; 2017 Dec; 72(6):888-896. PubMed ID: 28400169
[TBL] [Abstract][Full Text] [Related]
7. Negative Predictive Value of Prostate Multiparametric Magnetic Resonance Imaging among Men with Negative Prostate Biopsy and Elevated Prostate Specific Antigen: A Clinical Outcome Retrospective Cohort Study.
Lo G; Burton KR; Haider MA; Fleshner N; Finelli A; Ghai S
J Urol; 2019 Dec; 202(6):1159-1165. PubMed ID: 31188731
[TBL] [Abstract][Full Text] [Related]
8. The diagnostic accuracy of multiparametric magnetic resonance imaging before biopsy in the detection of prostate cancer.
Otti VC; Miller C; Powell RJ; Thomas RM; McGrath JS
BJU Int; 2019 Jan; 123(1):82-90. PubMed ID: 29804315
[TBL] [Abstract][Full Text] [Related]
9. Multiparametric magnetic resonance imaging guided diagnostic biopsy detects significant prostate cancer and could reduce unnecessary biopsies and over detection: a prospective study.
Thompson JE; Moses D; Shnier R; Brenner P; Delprado W; Ponsky L; Pulbrook M; Böhm M; Haynes AM; Hayen A; Stricker PD
J Urol; 2014 Jul; 192(1):67-74. PubMed ID: 24518762
[TBL] [Abstract][Full Text] [Related]
10. Which Patients with Negative Magnetic Resonance Imaging Can Safely Avoid Biopsy for Prostate Cancer?
Oishi M; Shin T; Ohe C; Nassiri N; Palmer SL; Aron M; Ashrafi AN; Cacciamani GE; Chen F; Duddalwar V; Stern MC; Ukimura O; Gill IS; Luis de Castro Abreu A
J Urol; 2019 Feb; 201(2):268-276. PubMed ID: 30189186
[TBL] [Abstract][Full Text] [Related]
11. Prostate cancer gene 3 and multiparametric magnetic resonance can reduce unnecessary biopsies: decision curve analysis to evaluate predictive models.
Busetto GM; De Berardinis E; Sciarra A; Panebianco V; Giovannone R; Rosato S; D'Errigo P; Di Silverio F; Gentile V; Salciccia S
Urology; 2013 Dec; 82(6):1355-60. PubMed ID: 24080222
[TBL] [Abstract][Full Text] [Related]
12. PCA3 molecular urine test as a predictor of repeat prostate biopsy outcome in men with previous negative biopsies: a prospective multicenter clinical study.
Gittelman MC; Hertzman B; Bailen J; Williams T; Koziol I; Henderson RJ; Efros M; Bidair M; Ward JF
J Urol; 2013 Jul; 190(1):64-9. PubMed ID: 23416644
[TBL] [Abstract][Full Text] [Related]
13. Is it Time to Perform Only Magnetic Resonance Imaging Targeted Cores? Our Experience with 1,032 Men Who Underwent Prostate Biopsy.
Pepe P; Garufi A; Priolo GD; Galia A; Fraggetta F; Pennisi M
J Urol; 2018 Oct; 200(4):774-778. PubMed ID: 29679618
[TBL] [Abstract][Full Text] [Related]
14. Negative Prebiopsy Magnetic Resonance Imaging and Risk of Significant Prostate Cancer: Baseline and Long-Term Followup Results.
Buisset J; Norris JM; Puech P; Leroy X; Ramdane N; Drumez E; Villers A; Olivier J
J Urol; 2021 Mar; 205(3):725-731. PubMed ID: 33080153
[TBL] [Abstract][Full Text] [Related]
15. Negative Multiparametric Magnetic Resonance Imaging for Prostate Cancer: What's Next?
Panebianco V; Barchetti G; Simone G; Del Monte M; Ciardi A; Grompone MD; Campa R; Indino EL; Barchetti F; Sciarra A; Leonardo C; Gallucci M; Catalano C
Eur Urol; 2018 Jul; 74(1):48-54. PubMed ID: 29566957
[TBL] [Abstract][Full Text] [Related]
16. Prostate cancer gene 3 (PCA3) is of additional predictive value in patients with PI-RADS grade III (intermediate) lesions in the MR-guided re-biopsy setting for prostate cancer.
Kaufmann S; Bedke J; Gatidis S; Hennenlotter J; Kramer U; Notohamiprodjo M; Nikolaou K; Stenzl A; Kruck S
World J Urol; 2016 Apr; 34(4):509-15. PubMed ID: 26267808
[TBL] [Abstract][Full Text] [Related]
17. [Does PCA3 score and prostatic MRI help selection of patients scheduled for initial prostatic biopsy?].
Vinet M; Vlaeminck-Guillem V; Rouvière O; Perrin P; Paparel P; Devonec M; Adam E; Briant PE; Ruffion A
Prog Urol; 2013 Feb; 23(2):121-7. PubMed ID: 23352305
[TBL] [Abstract][Full Text] [Related]
18. A comparative performance analysis of total prostate-specific antigen, percentage free prostate-specific antigen, prostate-specific antigen velocity and urinary prostate cancer gene 3 in the first, second and third repeat prostate biopsy.
Auprich M; Augustin H; Budäus L; Kluth L; Mannweiler S; Shariat SF; Fisch M; Graefen M; Pummer K; Chun FK
BJU Int; 2012 Jun; 109(11):1627-35. PubMed ID: 21939492
[TBL] [Abstract][Full Text] [Related]
19. High prostate cancer gene 3 (PCA3) scores are associated with elevated Prostate Imaging Reporting and Data System (PI-RADS) grade and biopsy Gleason score, at magnetic resonance imaging/ultrasonography fusion software-based targeted prostate biopsy after a previous negative standard biopsy.
De Luca S; Passera R; Cattaneo G; Manfredi M; Mele F; Fiori C; Bollito E; Cirillo S; Porpiglia F
BJU Int; 2016 Nov; 118(5):723-730. PubMed ID: 27112799
[TBL] [Abstract][Full Text] [Related]
20. Value of PCA3 to predict biopsy outcome and its potential role in selecting patients for multiparametric MRI.
Leyten GH; Wierenga EA; Sedelaar JP; van Oort IM; Futterer JJ; Barentsz JO; Schalken JA; Mulders PF
Int J Mol Sci; 2013 May; 14(6):11347-55. PubMed ID: 23759986
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
